Perrigo Company (PRGO)
Perrigo Company R&D Expense: 27.95M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PRGO R&D Expense Rankings
| Overall | 17th percentile | 1463 of 1764 |
| Sector | 16th percentile | 343 of 413 in Healthcare |
| Industry | 0th percentile | 5 of 5 in Drug Related Products |
PRGO R&D Expense Range, Past 5 Years
| Minimum | 16.14M | Dec 2007 |
| Maximum | 31.15M | Dec 2011 |
| Average | 21.13M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these PRGO related companies
PRGO News
$PRGO Insider Sale: $1.6M of stock sold by Joseph Papa on May 21, 2012 http://stks.co/3xaX
about 3 days ago by MarketBrief
about 3 days ago by MarketBrief
Perrigo (PRGO) Gets Final FDA Approval for Generic Prevacid Caps (NVS)
May 18, 1:36PM Street Insider
May 18, 1:36PM Street Insider
Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
May 18, 1:33PM Benzinga
May 18, 1:33PM Benzinga
$PRGO http://stks.co/3reG shorted at 102.61. Right now still consolidating at the resistance.
about 10 days ago by hpymaggie
about 10 days ago by hpymaggie
$TARO Mispriced -> http://stks.co/3rbz $TEVA $PRGO $VTUS $PFE $AMRN
about 10 days ago by imhobutdydd
about 10 days ago by imhobutdydd
UPDATE: Stifel Nicolaus Initiates Perrigo Company with Buy, $125 PT; Leading Store Brand Pharma
May 15, 10:28AM Benzinga
May 15, 10:28AM Benzinga
Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
May 15, 10:13AM PR Newswire
May 15, 10:13AM PR Newswire
$TARO A Tale of 2 Public companies -> http://stks.co/3oYE $TEVA $PRGO $VTUS $PFE $AMRN
about 12 days ago by imhobutdydd
about 12 days ago by imhobutdydd
Nasdaq: oversold stocks in uptrend $AAPL $SBUX $PRGO http://stks.co/3nYm
about 14 days ago by mktgeist
about 14 days ago by mktgeist
Correction - Canaccord Genuity maintains a 'Hold' on ISIS Pharmaceuticals (ISIS)
May 09, 9:55AM Street Insider
May 09, 9:55AM Street Insider
Needham & Company Maintains a 'Hold' on Perrigo Co. (PRGO); Disappoints on Top-line Expectations
May 09, 8:22AM Street Insider
May 09, 8:22AM Street Insider
$TARO A Tale of 2 Public companies -> http://stks.co/3jVy $TEVA $PRGO $MYL $PFE $AMRN
about 18 days ago by imhobutdydd
about 18 days ago by imhobutdydd
$PRGO 3Q profit up from year ago as new product launches boosted sales. Outlook raised. http://stks.co/3jRW
about 18 days ago by abubnic
about 18 days ago by abubnic
$PRGO Mentioned more than normal on StockTwits - Currently at 13 x average daily social activity
about 18 days ago by TradeIdeasQuant
about 18 days ago by TradeIdeasQuant
$PRGO 200 Day SMA Cross - Price crossed below 200 day SMA (96.6536). Confirmed by volume.
about 18 days ago by TradeIdeasQuant
about 18 days ago by TradeIdeasQuant
$PRGO cuts revenue growth below guidance due to historically mild flu season but raises FY 2012 EPS.
about 18 days ago by abubnic
about 18 days ago by abubnic
$PRGO being accumulated by institutions *before* earnings. Always a good sign.
about 19 days ago by abubnic
about 19 days ago by abubnic
$PRGO to release quarterly earnings report on Tue, May 8 w conference call @ 10 am. http://stks.co/3gfp
about 21 days ago by abubnic
about 21 days ago by abubnic
$PRGO MACDBull Chart pat Strong Up Trend RSI Bull
Up/Down volume under Accum 50/200 day MA Bullish Support 104.10 Resistance at 108.62
about 27 days ago by MACDaddy
about 27 days ago by MACDaddy
Top Trade Ideas for the Week of April 30, 2012: The Rest | via @harmongreg http://stks.co/3ZUe $DD $DFS $DG $MLNX $PRGO
about 27 days ago by STNet
about 27 days ago by STNet
Top Trade Ideas for the Week of April 30, 2012: The Rest http://stks.co/3ZSG $DD $DFS $DG $MLNX $PRGO
about 27 days ago by harmongreg
about 27 days ago by harmongreg
Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
Apr 24, 11:01AM PR Newswire
Apr 24, 11:01AM PR Newswire
Perrigo Announces the Launch of Guaifenesin Extended-Release 600mg Tablets -- to Compare to Mucinex® 600mg
Apr 12, 2:10PM PR Newswire
Apr 12, 2:10PM PR Newswire
Canaccord Genuity Reiterates a 'Buy' on Perrigo Co. (PRGO); Meeting With Mgmt Confirms Solid Earnings Story
Mar 27, 9:01AM Street Insider
Mar 27, 9:01AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PRGO | 103.00 | +0.08 | +0.08% | 9.610B |
| PRGN | 0.58 | +0.00 | +0.83% | 34.72M |
| PRFT | 11.57 | +0.10 | +0.87% | 361.79M |
| PRF | 56.28 | -0.01 | -0.02% | |
| PRE | 72.31 | +0.30 | +0.42% | 4.728B |
| PRCP | 5.26 | +0.03 | +0.57% | 44.18M |
| PPT | 5.41 | -0.04 | -0.73% | |
| POWL | 34.81 | -0.13 | -0.37% | 409.02M |
| POT | 39.78 | -0.42 | -1.04% | 34.16B |
| PNSN | 0.2401 | -0.06 | -19.91% | 6.718M |
